Literature DB >> 22484776

Radiofrequency ablation procedures in Greece: initial experience and results from the national registry 2008-2010.

Vassilios P Vassilikos1, Michalis Efremidis, Lilian Mantziari, Andonios Billis, George Theodorakis, Apostolos Katzivas, Stylianos Paraskevaidis, Themistoklis Maounis, Efthymios Livanis, Antonis Manolis, Eleni Chatzinikolaou, Spyidon Defteraios, Demosthenes Katritsis, Emmanouil Kanoupakis, Ioannis Papagiannis, Nikolaos Frangakis, Konstandinos Gatzoulis, Nikolaos Dagres, Theodoros Apostolopoulos, Stylianos Rokas, Stella Gaitanidou, Ioannis Chiladakis, Dionisios Kalpakos, George Sakadamis, George Kourgianidis.   

Abstract

INTRODUCTION: In 2008 the radiofrequency ablation procedures (RFA) registry of the Hellenic Cardiological Society (HCS) was created. This is a dynamic, web-based application, which acts as the interface for storing and retrieving patients' demographic data and ablation procedures. Access to the site is permitted only to registered users. The purpose of this study is to report the results of RFA procedures performed in Greece over the 2008-2010 period.
METHODS: There are 27 centers in 24 hospitals that are licensed to perform RFA in Greece. During the period 2008-2010, 3541 RFA procedures were performed in 3344 patients in 23 centers. Four centers did not contribute data at all for various reasons. It is interesting that nearly 50% of the total number of procedures were performed at 3 high volume centers (>100 cases/year).
RESULTS: The most common procedure was slow pathway ablation for atrioventricular reentrant tachycardia, the second was ablation of accessory pathway related tachycardias, and the third was ablation of atrial fibrillation. Success rates were high (92.1%), the complication rate was 3% (serious complications <1%) and total relapse rate was 8.7% at six months' follow up.
CONCLUSIONS: The electronic RFA registry in Greece confirmed that all RFA procedures are performed in Greece with high success and low complication rates, comparable to the European and US standards. The experience and results from the first three-year period using the registry are very interesting and encouraging, thus indicating the need for development of similar databases at the national level.

Entities:  

Mesh:

Year:  2012        PMID: 22484776

Source DB:  PubMed          Journal:  Hellenic J Cardiol        ISSN: 1109-9666


  2 in total

1.  Snapshot of adult invasive cardiac electrophysiology in Canada: results of the web-based registry.

Authors:  Mohammed Shurrab; Evgeny Fishman; Anna Kaoutskaia; David Birnie; Felix Ayala-Paredes; Omar Sultan; Vijay Chauhan; Allan Skanes; Ratika Parkash; Carlos Morillo; Amir Janmohamed; Satish Toal; Vidal Essebag; Laurence Sterns; George Veenhuyzen; Iqwal Mangat; Damian Redfearn; François Philippon; Sean Connors; Jeff Healey; Atul Verma; Eugene Crystal
Journal:  J Interv Card Electrophysiol       Date:  2014-04-22       Impact factor: 1.900

2.  Effect of the COVID-19 pandemic on cardiac electrophysiological ablation procedures in Greece - Data from the Hellenic Society of Cardiology Ablation Registry.

Authors:  Vassilios P Vassilikos; Georgios Giannopoulos; Nikolaos Fragakis; Antonis Billis; Michalis Efremidis; Konstantinos Letsas; Themistoklis Maounis; Anna Kostopoulou; Georgios Andrikopoulos; Sokratis Pastromas; Apostolos Katsivas; Charalambos Kossyvakis; Eleftherios Kallergis; Emmanouel Kanoupakis; Panagiotis Ioannidis; Stelios Tzeis; Dimosthenis Avramidis; Ioannis Papagiannis; Spyridon Deftereos; Eftychia Symeonidou; Dimitrios Tsiachris; George Theodorakis; Ioannis Rassias; Dimitrios Lysitsas; Eleni Chatzinikolaou; Nikolaos Mezilis; Stylianos Paraskevaidis; Spyros Kourouklis; Theodoros Apostolopoulos; Dimosthenis Katritsis; Sophia Chatzidou; Lilian Mantziari; Georgios Leventopoulos; Ioannis Chiladakis; George Kourgiannidis; George Stavropoulos; Sotirios Xydonas; Charilaos Ginos; Athanasios Kotsakis; Giannis Baltogiannis; Antonis S Manolis; Skevos Sideris; Konstantinos Gatzoulis
Journal:  Hellenic J Cardiol       Date:  2022-07-08       Impact factor: 5.795

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.